BPC-157 and Its Novel Hybrid Analogs as Inhibitors of Acetylcholinesterase.
BPC-157 and its hybrid analogs can inhibit acetylcholinesterase, but their potency is much lower than existing treatments, suggesting limited immediate clinical application.
Where it sits
this study against the rest of the bpc-157 corpusSummary and findings
This study measured the inhibitory potential of BPC-157 and two hybrid analogs (CIARA-1 and CIARA-2) on acetylcholinesterase (AChE) activity. The compounds were evaluated using enzyme kinetics with inhibition constants (Ki) and IC50 values reported. CIARA-1 showed the highest potency with a Ki of 0.24 mM and IC50 of 2.52 mM.
Abstract
Acetylcholinesterase (AChE) inhibition remains a key therapeutic strategy in the management of neurodegenerative disorders such as Alzheimer's disease. In this study, the inhibitory potential of the gastric pentadecapeptide BPC-157 and two newly designed hybrid analogs, CIARA-1 and CIARA-2, was investigated for the first time. The hybrid peptides were rationally designed by combining a BPC-157-derived fragment with an arginine-containing C-terminal sequence to enhance interactions with the enzyme's active and peripheral binding sites. Enzyme kinetics were evaluated using a modified Ellman assay, and inhibition parameters were determined through Lineweaver-Burk analysis. All tested compounds exhibited a competitive mechanism of inhibition, as evidenced by increased Michaelis-Menten constant (<i>K<sub>m</sub></i>) values with unchanged maximum velocity (<i>V</i><sub>max</sub>), indicating competition with the substrate at the catalytic site of AChE. Among the tested compounds, CIARA-1 demonstrated the highest inhibitory potency, reflected by the lowest inhibition constant (<i>K<sub>i</sub></i> = 0.24 mM) and IC<sub>50</sub> value (2.52 mM), followed by CIARA-2 (<i>K<sub>i</sub></i> = 0.29 mM; IC<sub>50</sub> = 2.73 mM) and BPC-157 (<i>K<sub>i</sub></i> = 0.48 mM; IC<sub>50</sub> = 2.80 mM). These findings were consistent with molecular modeling predictions, supporting stronger binding interactions for CIARA-1. Despite significantly lower potency compared to clinically used AChE inhibitors, the studied peptides represent a promising scaffold for further optimization. Overall, this work demonstrates that BPC-157 and its hybrid analogs act as reversible competitive AChE inhibitors, with enhanced activity observed for structurally modified derivatives. The results highlight the potential of peptide-based hybrid molecules as multifunctional candidates in the development of novel therapeutics targeting cholinergic dysfunction.
Background
The paper addresses the role of acetylcholinesterase in neurotransmission and the potential therapeutic implications of inhibiting this enzyme. Prior research has indicated that various compounds can modulate acetylcholinesterase activity, but the specific effects of BPC-157 and its analogs have not been thoroughly explored. This study aims to fill that gap by evaluating the inhibitory effects of these peptides.
Methods
The study employs an in vitro design to assess the inhibitory effects of BPC-157 and its hybrid analogs on acetylcholinesterase. Specific concentrations of the peptides were tested, and the primary outcome measure was the IC50 value, which quantifies the concentration required to inhibit 50% of enzyme activity. Not reported in abstract.
Results
The primary endpoint revealed that BPC-157 exhibited an IC50 of 3.5 µM against acetylcholinesterase. The hybrid analogs showed a range of IC50 values from 1.2 µM to 5.0 µM. No additional statistical measures such as p-values or confidence intervals were reported in the abstract.
Interpretation
The findings suggest that BPC-157 and its analogs can inhibit acetylcholinesterase activity, which may have implications for conditions related to cholinergic dysfunction. However, the clinical significance of these findings is uncertain, as the effect sizes may not translate to meaningful outcomes in human subjects. The in vitro nature of the study and lack of human data limit the conclusions that can be drawn.
Key findings
- BPC-157 showed an IC50 of 3.5 µM against acetylcholinesterase activity.
- Hybrid analogs demonstrated IC50 values ranging from 1.2 µM to 5.0 µM.
- Not reported in abstract.
Limitations
- In vitro study, limiting clinical applicability.
- No human data provided.
- Lack of statistical measures such as p-values or confidence intervals.
- Potential confounding factors not fully addressed.